Fig. 3: Overexpression of SLC25A10 can increase the resistance of cervical cancer cells to cisplatin.
From: SLC25A10 promotes cisplatin resistance by inhibiting ferroptosis in cervical cancer
After 24 h of treatment with different concentrations of DDP, the viability of SLC25A10-overexpressing cells and those with SLC25A10 knockdown was determined by CCK-8 assay (A, B). Cervical cancer cells treated with 4 mg/DDP for 16 h and cultured for 2 weeks were cloned, and the results were quantified (C–E). Compared with the control group, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. Scale =200 µm. The data represent the means ± SDs.
